A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease
The study treatment period is 15 days in length and includes patients with pituitary Cushing's disease who are candidates for surgical intervention as well as and patients who have recurrent Cushing's post operatively.
Cushing's Syndrome
DRUG: SOM230 s.c.
Urinary Free Cortisol after 15 days of treatment
Serum cortisol|ACTH|Clinical manifestations|Pharmacokinetics|Safety|Tolerability|Development of biomarkers
The study treatment period is 15 days in length and includes patients with pituitary Cushing's disease who are candidates for surgical intervention as well as and patients who have recurrent Cushing's post operatively.